IAG Partners with Leading Academics to Provide AI-powered MRI Analysis of Scleroderma
Image Analysis Group, has established itself as a leading expert in imaging biomarkers for scleroderma and autoimmune diseases through a strategic partnership with the University of Leeds. This collaboration highlights IAG’s commitment to advancing research and clinical trials in these challenging areas:
-
Innovative Imaging Biomarker: IAG and Leeds researchers have developed DAVIX (Digital Artery Volume Index), a novel MRI-based technique for quantifying digital artery volume without contrast agents. This tool offers a more precise assessment of vascular changes in scleroderma patients.
-
AI-Powered Analysis: IAG is applying state-of-the-art machine learning to create an operator-independent tool for scleroderma image quantification, enhancing the reliability and feasibility of scleroderma MRIs.
-
Integration with DYNAMIKA: The new imaging tool will be incorporated into IAG’s proprietary cloud platform DYNAMIKA, streamlining data management and analysis for clinical trials.
-
Market Potential: With the global scleroderma diagnostics and therapeutics market projected to reach $3,663.7 million by 2024, IAG is well-positioned to support pharmaceutical companies in developing and testing new treatments.
-
Validation for Clinical Use: The partnership aims to meet OMERACT (Outcome Measure in Rheumatology Consortium) criteria, potentially establishing DAVIX as a standardized outcome measure for international clinical trials.
By leveraging this advanced imaging technology and expertise, IAG offers pharmaceutical companies developing treatments for scleroderma and other autoimmune diseases a powerful tool to accelerate clinical trials, improve patient stratification, and provide earlier, more accurate assessments of treatment efficacy.
Computer model of fingers automatically calculated from MRI images of patients with scleroderma using IAG advanced algorithms (DYNAMIKA)